1. Home
  2. XNCR

as of 12-04-2025 3:46pm EST

$18.36
+$1.05
+6.07%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Chart Type:
Time Range:
Founded: 1997 Country:
United States
United States
Employees: N/A City: PASADENA
Market Cap: 1.1B IPO Year: 2013
Target Price: $23.20 AVG Volume (30 days): 758.3K
Analyst Decision: Buy Number of Analysts: 11
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.77 EPS Growth: N/A
52 Week Low/High: $6.92 - $27.24 Next Earning Date: 11-05-2025
Revenue: $150,132,000 Revenue Growth: 38.16%
Revenue Growth (this year): 22.09% Revenue Growth (next year): -10.26%

AI-Powered XNCR Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 80.14%
80.14%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: